Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years

被引：0
|
作者：
Wollenhaupt, Juergen [1 ]
Silverfield, Joel [2 ]
Lee, Eun Bong [3 ]
Terry, Ketti [4 ]
Kwok, Kenneth [5 ]
Abramsky, Staci [5 ]
Wang, Min [5 ]
Nduaka, Chudy [6 ]
DeMasi, Ryan [5 ]
Wang, Lisy [4 ]
机构：
[1] Univ Hamburg, Eilbek Teaching Hosp, Schoen Klin Hamburg, Hamburg, Germany
[2] Healthpoint Med Grp, Tampa, FL USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Collegeville, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1647
引用
收藏
页数：3
相关论文
共 50 条
  • [1] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 8 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K.
    Kwok, K.
    Abramsky, S.
    Wang, M.
    Nduaka, C.
    DeMasi, R.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 277 - 278
  • [2] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Terry, Ketti
    Kwok, Kenneth
    Strengholt, Sander
    DeMasi, Ryan
    Wang, Lisy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [3] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 9 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K.
    Kwok, K.
    Strengholt, S.
    DeMasi, R.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 978 - 978
  • [4] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Terry, Ketti
    Kwok, Kenneth
    Lazariciu, Irina
    Nduaka, Chudy
    Connell, Carol A.
    DeMasi, Ryan
    Wang, Lisy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [5] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [6] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [7] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Riese, R.
    Wang, L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
  • [8] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Curtis, Jeffrey R.
    Wood, Susan P.
    Soma, Koshika
    Nduaka, Chudy I.
    Benda, Birgitta
    Gruben, David
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Zwillich, Samuel H.
    Wang, Lisy
    Riese, Richard J.
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 837 - 852
  • [9] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
    Wollenhaupt, Jurgen
    Silverfield, Joel C.
    Lee, Eun Bong
    Wood, Susan P.
    Soma, Koshika
    Wang, Lisy
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Nduaka, Chudi I.
    Gruben, David
    Benda, Birgitta
    Zwillich, Samuel H.
    Riese, Richard
    Bradley, John D.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549
  • [10] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, P.
    Genovese, M. C.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 66
12345